Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123675
Filing Date
2024-11-08
Accepted
2024-11-08 06:50:23
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q igms-20240930.htm   iXBRL 10-Q 2609930
2 EX-10.1 igms-ex10_1.htm EX-10.1 134728
3 EX-10.2 igms-ex10_2.htm EX-10.2 34426
4 EX-10.3 igms-ex10_3.htm EX-10.3 132978
5 EX-10.4 igms-ex10_4.htm EX-10.4 59319
6 EX-31.1 igms-ex31_1.htm EX-31.1 15046
7 EX-31.2 igms-ex31_2.htm EX-31.2 13944
8 EX-32.1 igms-ex32_1.htm EX-32.1 8633
9 EX-32.2 igms-ex32_2.htm EX-32.2 8602
  Complete submission text file 0000950170-24-123675.txt   9603179

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT igms-20240930.xsd EX-101.SCH 1321908
72 EXTRACTED XBRL INSTANCE DOCUMENT igms-20240930_htm.xml XML 1463609
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39045 | Film No.: 241437932
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)